EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitVergleichsstudie

Romosozumab versus parathyroid hormone receptor agonists: which osteoanabolic to choose and when?

Athanasios D Anastasilakis iD, Maria P Yavropoulou iD, Andrea Palermo iD, Polyzois Makras iD, Julien Paccou iD, Gaia Tabacco iD, Anda Mihaela Naciu iD, Elena Tsourdi iD

European Journal of Endocrinology · 02.07.2024 · 191 (1) · R9-R21

DOI: 10.1093/ejendo/lvae076 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Endocrinology, online erschienen am 28.06.2024. Verfasst von Athanasios D Anastasilakis und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, 424 Military General Hospital, Thessaloniki 564 29, Greece. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Bone Density Conservation Agents, Bone Density, Teriparatide. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 120 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osteoanabolic agents are used as a first line treatment in patients at high fracture risk. The PTH receptor 1 (PTH1R) agonists teriparatide (TPTD) and abaloparatide (ABL) increase bone formation, bone mineral density (BMD), and bone strength by activating PTH receptors on osteoblasts. Romosozumab (ROMO), a humanized monoclonal antibody against sclerostin, dramatically but transiently stimulates bone formation and persistently reduces bone resorption. Osteoanabolic agents increase BMD and bone strength while being more effective than antiresorptives in reducing fracture risk in postmenopausal women. However, direct comparisons of the antifracture benefits of osteoanabolic therapies are limited. In a direct comparison of TPTD and ABL, the latter resulted in greater BMD increases at the hip. While no differences in vertebral or non-vertebral fracture risk were observed between the two drugs, ABL led to a greater reduction of major osteoporotic fractures. Adverse event profiles were similar between the two agents except for hypercalcemia, which occurred more often with TPTD. No direct comparisons of fracture risk reduction between ROMO and the PTH1R agonists exist. Individual studies have shown greater increases in BMD and bone strength with ROMO compared with TPTD in treatment-naive women and in women previously treated with bisphosphonates. Some safety aspects, such as a history of tumor precluding the use of PTH1R agonists, and a history of major cardiovascular events precluding the use of ROMO, should also be considered when choosing between these agents. Finally, convenience of administration, reimbursement by national health systems and length of clinical experience may influence patient choice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalBone Density Conservation AgentsBone DensityTeriparatideReceptor, Parathyroid Hormone, Type 1HumansFemaleOsteoporotic FracturesParathyroid Hormone-Related ProteinOsteoporosis, Postmenopausal

Stichwörter der Autor:innen

abaloparatideanabolicbone mineral densityosteoporosisromosozumabteriparatide

Substanzen

romosozumabAntibodies, MonoclonalBone Density Conservation AgentsTeriparatideabaloparatideReceptor, Parathyroid Hormone, Type 1Parathyroid Hormone-Related Protein

Autor:innen und Institutionen

  • Department of Endocrinology, 424 Military General Hospital, Thessaloniki 564 29, Greece.
  • Endocrinology Unit, 1st Department of Propaedeutic and Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Laikon University Hospital of Athens, Athens 115 27, Greece.
  • Unit of Metabolic Bone and Thyroid Diseases, Fondazione Policlinico Universitario Campus Bio-Medico, Rome 00128, Italy.
  • Unit of Endocrinology and Diabetes, Campus Bio-Medico University of Rome, Rome 00128, Italy.
  • Department of Medical Research, 251 Hellenic Air Force & VA General Hospital, Athens 115 25, Greece.
  • Department of Rheumatology, CHU Lille, Lille 59000, France.

ORCID-Profile: Athanasios D Anastasilakis, Maria P Yavropoulou, Andrea Palermo, Polyzois Makras, Julien Paccou, Gaia Tabacco, Anda Mihaela Naciu, Elena Tsourdi

Zitieren

APA

Anastasilakis, A. D., Yavropoulou, M. P., Palermo, A., Makras, P., Paccou, J., Tabacco, G., Naciu, A. M., & Tsourdi, E. (2024). Romosozumab versus parathyroid hormone receptor agonists: which osteoanabolic to choose and when?. European Journal of Endocrinology, 191(1), R9-R21. https://doi.org/10.1093/ejendo/lvae076

Vancouver

Anastasilakis AD, Yavropoulou MP, Palermo A, Makras P, Paccou J, Tabacco G, et al. Romosozumab versus parathyroid hormone receptor agonists: which osteoanabolic to choose and when?. European Journal of Endocrinology. 2024;191(1):R9-R21. doi:10.1093/ejendo/lvae076

BibTeX
@article{Anastasilakis2024,
  author = {Anastasilakis, Athanasios D and Yavropoulou, Maria P and Palermo, Andrea and Makras, Polyzois and Paccou, Julien and Tabacco, Gaia and Naciu, Anda Mihaela and Tsourdi, Elena},
  title = {Romosozumab versus parathyroid hormone receptor agonists: which osteoanabolic to choose and when?},
  journal = {European Journal of Endocrinology},
  year = {2024},
  volume = {191},
  number = {1},
  pages = {R9--R21},
  doi = {10.1093/ejendo/lvae076}
}
Kostenlos starten →